Sign in
GLMD Stock Price, Chart, Stats & News
Galmed Pharmaceuticals Ltd.
Save
3.18M
Market cap
–
Current P/E
–
Forward P/E
GLMD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -40.31% |
ROE | -47.78% |
D/E | – |
Interest coverage ratio | -15.70x |
GLMD valuation
P/E | – |
P/S | – |
P/B | 0.14x |
P/CF | -0.43x |
P/FCF | -0.44x |
P/OCF | -0.43x |
PEG | -0.01x |
EV multiple | -0.86x |
About
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug currently undergoing Phase III clinical trials. This pivotal study is for the treatment of non-alcoholic steato-hepatitis (NASH) in individuals who are overweight or obese and also present with pre-diabetes or type 2 diabetes.
Similar securities
Based on sector and market capitalization
Report issue